Find Ubrogepant manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1374248-77-7, Ubrelvy, Mk-1602, Ubrogepant anhydrous, Ad0o8x2qjr, (3's)-n-((3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro(cyclopenta(b)pyridine-6,3'-pyrrolo(2,3-b)pyridine)-3-carboxamide
Molecular Formula
C29H26F3N5O3
Molecular Weight
549.5  g/mol
InChI Key
DDOOFTLHJSMHLN-ZQHRPCGSSA-N
FDA UNII
AD0O8X2QJR

Ubrogepant
Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant] remain in clinical development. Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative to its predecessors. Several parenteral monoclonal antibodies acting against the CGRP pathway (e.g. [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years. Compared to the current standard of therapy for migraine treatment, namely triptans such as [sumatriptan] and [almotriptan], CGRP antagonists present several advantages. They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular disease. The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment of this debilitating condition.
Ubrogepant is a Calcitonin Gene-related Peptide Receptor Antagonist. The mechanism of action of ubrogepant is as a Calcitonin Gene-related Peptide Receptor Antagonist.
1 2D Structure

Ubrogepant

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
2.1.2 InChI
InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1
2.1.3 InChI Key
DDOOFTLHJSMHLN-ZQHRPCGSSA-N
2.1.4 Canonical SMILES
CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6
2.1.5 Isomeric SMILES
C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6
2.2 Other Identifiers
2.2.1 UNII
AD0O8X2QJR
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1',2',5,7-tetrahydro-n-((3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl)-2'-oxo-, (6s)- Spiro(6h-cyclopenta(b)pyridine-6,3'-(3h)pyrrolo(2,3-b)pyridine)-3-carboxamide

2. Mk-1602

3. Ubrelvy

2.3.2 Depositor-Supplied Synonyms

1. 1374248-77-7

2. Ubrelvy

3. Mk-1602

4. Ubrogepant Anhydrous

5. Ad0o8x2qjr

6. (3's)-n-((3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro(cyclopenta(b)pyridine-6,3'-pyrrolo(2,3-b)pyridine)-3-carboxamide

7. (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide

8. Spiro(6h-cyclopenta(b)pyridine-6,3'-(3h)pyrrolo(2,3-b)pyridine)-3-carboxamide, 1',2',5,7-tetrahydro-n-((3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl)-2'-oxo-, (3's)-

9. Ubrogepant [usan]

10. Ubrogepant [usan:inn]

11. Unii-ad0o8x2qjr

12. Ubrelvy (tn)

13. Ubrogepant [mi]

14. Ubrogepant [inn]

15. Ubrogepant (usan/inn)

16. Ubrogepant [who-dd]

17. Schembl3698428

18. Chembl2364638

19. Ubrogepant [orange Book]

20. Gtpl10176

21. Dtxsid00160178

22. Ex-a3049

23. Mfcd28386182

24. Mk1602

25. Zinc95598454

26. At16059

27. Db15328

28. Ac-31965

29. Hy-12366

30. Cs-0011109

31. D10673

32. A934103

33. Q27273878

34. S-1374248-77-7

35. (6s)-n-[(3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide

36. (s)-n-((3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide

2.4 Create Date
2012-11-30
3 Chemical and Physical Properties
Molecular Weight 549.5 g/mol
Molecular Formula C29H26F3N5O3
XLogP33.1
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count4
Exact Mass549.19877419 g/mol
Monoisotopic Mass549.19877419 g/mol
Topological Polar Surface Area104 Ų
Heavy Atom Count40
Formal Charge0
Complexity1000
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Ubrogepant is indicated for the acute treatment of migraine with or without aura in adults.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Ubrogepant acutely treats migraine headache pain by blocking the activity of a key transmitter involved in migraine pathogenesis. Exposure to ubrogepant can be significantly increased in patients with severe hepatic or renal insufficiency - dose adjustments are required for these patients in order to avoid excessive exposure, and ubrogepant is not recommended in patients with end-stage renal disease.


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
UBROGEPANT
5.2.2 FDA UNII
AD0O8X2QJR
5.2.3 Pharmacological Classes
Mechanisms of Action [MoA] - Calcitonin Gene-related Peptide Receptor Antagonists
5.3 ATC Code

N - Nervous system

N02 - Analgesics

N02C - Antimigraine preparations

N02CD - Calcitonin gene-related peptide (cgrp) antagonists

N02CD04 - Ubrogepant


5.4 Absorption, Distribution and Excretion

Absorption

Following oral administration, Tmax occurs between 0.7 and 1.5 h. When administered with a high-fat meal, Tmax is delayed by approximately 2 hours and Cmax was reduced by 22% with no significant changes to the AUC. Ubrogepant exhibits dose-proportional pharmacokinetics throughout the entirety of its recommended dosing range.


Route of Elimination

The main route of elimination is fecal/biliary, while renal excretion is comparatively minor - following administration of a single oral dose to healthy subjects, approximately 42% of the dose was recovered unchanged in the feces and 6% was recovered unchanged in the urine.


Volume of Distribution

The apparent central volume of distribution following oral administration is approximately 350 L.


Clearance

The apparent oral clearance of ubrogepant is approximately 87 L/h.


5.5 Metabolism/Metabolites

Ubrogepant is eliminated primarily via metabolism, the majority of which is mediated by CYP3A4. Two circulating glucuronide conjugates, along with unchanged parent drug, were found to be the most abundant circulating components in human plasma. The glucuronide metabolites reportedly carry 6000-fold less activity at CGRP receptors and are therefore considered to be pharmacologically inert.


5.6 Biological Half-Life

Ubrogepant has an elimination half-life of 5-7 hours.


5.7 Mechanism of Action

The currently accepted theory of migraine pathophysiology considers dysfunction of the central nervous system, in particular the trigeminal ganglion, to be the root cause behind the condition. Activation of the trigeminal ganglion triggers the stimulation of trigeminal afferents that project to the spinal cord and synapse on various pain-sensing intra- and extracranial structures, such as the dura mater. Pain signals are then further transmitted via second-order ascending neurons to the brainstem, hypothalamus, and thalamic nuclei, and from there to several cortical regions (e.g. auditory, visual, motor cortices). The trigeminal ganglion appears to amplify and perpetuate the migraine headache pain through the activation of perivascular fibers and the release of molecules involved in pain generation, such as calcitonin gene-related peptide (CGRP). The -isoform of CGRP, expressed in primary sensory neurons, is a potent vasodilator and has been implicated in migraine pathogenesis - CGRP levels are acutely elevated during migraine attacks, return to normal following treatment with triptan medications, and intravenous infusions of CGRP have been shown to trigger migraine-like headaches in migraine patients. In addition to its vasodilatory properties, CGRP appears to be a pronociceptive factor that modulates neuronal excitability to facilitate pain responses. Ubrogepant is a potent antagonist of the calcitonin gene-related peptide receptor - it competes with CGRP for occupancy at these receptors, preventing the actions of CGRP and its ability to amplify and perpetuate migraine headache pain, ultimately terminating the headache.


USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2023-08-08

Pay. Date : 2023-06-16

DMF Number : 38498

Submission : 2023-06-23

Status : Active

Type : II

Company Banner

02

PREP
Not Confirmed

02

PREP
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-09-26

Pay. Date : 2023-08-09

DMF Number : 38648

Submission : 2023-08-11

Status : Active

Type : II

blank

03

PREP
Not Confirmed

03

PREP
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-08-31

Pay. Date : 2023-08-08

DMF Number : 38576

Submission : 2023-08-02

Status : Active

Type : II

blank

04

Allsino Pharmaceutical Co Ltd

Country

USDMF

arrow
PREP
Not Confirmed

04

Allsino Pharmaceutical Co Ltd

Country
arrow
PREP
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41936

Submission : 2025-06-24

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content

UBROGEPANT

NDC Package Code : 69037-0077

Start Marketing Date : 2019-12-23

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Company Banner

02

PREP
Not Confirmed
arrow
arrow
PREP
Not Confirmed

UBROGEPANT

NDC Package Code : 59651-860

Start Marketing Date : 2024-01-10

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (50kg/50kg)

Marketing Category : BULK INGREDIENT

blank

03

Ubrogepant

Country
PREP
Not Confirmed
arrow

Ubrogepant

Country
arrow
PREP
Not Confirmed

UBROGEPANT

NDC Package Code : 69766-109

Start Marketing Date : 2023-08-22

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

PMC Isochem

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

Flag France
Digital Content Digital Content

Ubrogepant

About the Company : PMC Isochem is a CDMO company acquired by PMC International in 2017. It manufactures cGMP intermediates, active pharmaceutical ingredients and functional excipients for pharmaceuti...

PMC Isochem is a CDMO company acquired by PMC International in 2017. It manufactures cGMP intermediates, active pharmaceutical ingredients and functional excipients for pharmaceutical and personal care companies worldwide. Its business includes research, product and process development, pilot-scale, industrial production and regulatory approvals support. It adds value to its clients' intellectual property through constant innovation in manufacturing techniques throughout the product life cycle. PMC Isochem's facilities are located within 60 miles of Paris and are all US FDA-audited plants.
PMC Isochem

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Ubrogepant

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

Flag China
Digital Content Digital Content

Ubrogepant

About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...

Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include customized R&D as well as the production of small molecule pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) for both international and domestic pharmaceutical firms. Our capabilities span from laboratory-scale kilograms to commercial ton-scale production. Additionally, we are committed to independent research and development, as well as the production and sales of high-end pharmaceutical intermediates and API products.
Jinan Tantu Chemicals

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content

Ubrogepant

About the Company : Honour is a leading global CDMO and a trusted manufacturer of specialty chemicals and ingredients. With seven world-class facilities built to meet global safety and quality standar...

Honour is a leading global CDMO and a trusted manufacturer of specialty chemicals and ingredients. With seven world-class facilities built to meet global safety and quality standards, we are committed to delivering excellence with innovative, holistic solutions to clients across the globe by leveraging our expertise in chemistry. Operating through our two core verticals - Honour Synthesis and Honour Specialty, we embrace the science of partnership and possibilities. Our team of over 2,500 professionals collaborates closely with pharmaceutical, biotechnology, and specialty industries worldwide to develop practical, scalable solutions.
Company Banner

05

PREP
Not Confirmed
arrow
arrow
PREP
Not Confirmed

Ubrogepant

About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...

Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
blank

06

PREP
Not Confirmed
arrow
arrow
PREP
Not Confirmed

Ubrogepant

About the Company : Hebi Xinhe Pharmaceutical Co., Ltd. is a subsidiary of Tianjin Zhennuo Pharmaceutical Group Co., Ltd., with a registered capital of CNY 100 million. Located in Jijiashan Industrial...

Hebi Xinhe Pharmaceutical Co., Ltd. is a subsidiary of Tianjin Zhennuo Pharmaceutical Group Co., Ltd., with a registered capital of CNY 100 million. Located in Jijiashan Industrial Park in Heshan District, Hebi City, the company spans 146,200 square meters, with a planned construction area of 80,300 square meters and a total investment of CNY 750 million. Our facilities include production plants, warehouses, office buildings, fire safety infrastructure, and waste treatment systems.
blank

07

PREP
Not Confirmed
arrow
arrow
PREP
Not Confirmed

Ubrogepant

About the Company : Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and effici...

Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and efficient manufacturing technologies, Sinopep ensures global compliance with advanced process development. Their CRDMO services span peptides, oligonucleotides, and synthetic conjugates, making them a trusted partner worldwide in pharmaceutical and healthcare solutions.
blank

08

PREP
Not Confirmed
arrow
arrow
PREP
Not Confirmed

Ubrogepant

About the Company : Micro Labs Limited is a diversified healthcare company with cutting-edge R&D, advanced manufacturing facilities, and a strong distribution network. It ranks among India's top pharm...

Micro Labs Limited is a diversified healthcare company with cutting-edge R&D, advanced manufacturing facilities, and a strong distribution network. It ranks among India's top pharmaceutical companies, with a leading presence in cardiology, diabetology, anti-infectives, ophthalmology, and pain management. The company is known for its high-quality medicines, including the popular fever management brand, Dolo. Micro Labs continues to grow through innovation, research, and global expansion, delivering healthcare solutions that meet international standards.
blank

09

PREP
Not Confirmed
arrow
arrow
PREP
Not Confirmed

Ubrogepant

About the Company : Founded in 2003, Zhejiang Tianyu Pharmaceutical Co., Ltd. is a joint-stock pharmaceutical company specializing in the research, development and manufacture of APIs and advanced pha...

Founded in 2003, Zhejiang Tianyu Pharmaceutical Co., Ltd. is a joint-stock pharmaceutical company specializing in the research, development and manufacture of APIs and advanced pharmaceutical intermediates. The company has a registered capital of 120 million yuan and covers an area of ​​700 mu. The factory has more than 2,600 employees.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1674757800,"product":"UBROGEPANT","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"KING PRIME GLOBAL PROCUREMENT TRADI","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.60","actualQuantity":"600","unit":"GMS","unitRateFc":"376","totalValueFC":"238272.1","currency":"EURO","unitRateINR":32468.333333333332,"date":"27-Jan-2023","totalValueINR":"19481000","totalValueInUsd":"238272.1","indian_port":"BOMBAY AIR","hs_no":"29337900","bill_no":"7304369","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675103400,"product":"UBROGEPANT","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"NEW YORK","customer":"HETERO USAINC","customerCountry":"UNITED STATES","quantity":"45.00","actualQuantity":"45","unit":"KGS","unitRateFc":"33000","totalValueFC":"1463033.5","currency":"USD","unitRateINR":2658151.888888889,"date":"31-Jan-2023","totalValueINR":"119616835","totalValueInUsd":"1463033.5","indian_port":"Vizag-HIPL SEZ","hs_no":"29335990","bill_no":"4000056","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1745173800,"product":"UBROGEPANT (UBR)","address":"PLOT NO.C-24, MSN HOUSE, INDUSTRIAL","city":"HYDERABAD, AP","supplier":"MSN LIFE SCIENCES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ST LOUIS","customer":"SPECGX LLC","customerCountry":"UNITED STATES","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"35000","totalValueFC":"3450.7","currency":"USD","unitRateINR":2953847.8999999994,"date":"21-Apr-2025","totalValueINR":"295384.79","totalValueInUsd":"3450.7","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"1119102","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.C-24, MSN HOUSE, INDUSTRIAL, HYDERABAD, AP","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652725800,"product":"UBROGEPANT AMINE INTERMEDIATE","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"ZHEJIANG SHINDAI CHEMICALS CO LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"MSN LABORATORIES PRIVATE LTD","customerCountry":"INDIA","quantity":"0.34","actualQuantity":"0.34","unit":"KGS","unitRateFc":"72000","totalValueFC":"24405.3","currency":"USD","unitRateINR":"5547600","date":"17-May-2022","totalValueINR":"1886184","totalValueInUsd":"24405.3","indian_port":"MADRAS AIR","hs_no":"29349990","bill_no":"8708577","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652725800,"product":"UBROGEPANT INTERMEDIATE","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"ZHEJIANG SHINDAI CHEMICALS CO LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"MSN LABORATORIES PRIVATE LTD","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"22200","totalValueFC":"22132.3","currency":"USD","unitRateINR":"1710510","date":"17-May-2022","totalValueINR":"1710510","totalValueInUsd":"22132.3","indian_port":"MADRAS AIR","hs_no":"29349990","bill_no":"8708577","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1658082600,"product":"UBROGEPANT INTERMEDIATE","address":"MSN HOUSE,PLOT NO.C-24,INDUSTRIAL E SANATH NAGAR,HYDERABAD","city":"HYDERABAD TS","supplier":"ZHEJIANG SHINDAI CHEMICALS CO LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"MSN LIFE SCIENCES PRIVATE LTD","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"18000","totalValueFC":"18086.8","currency":"USD","unitRateINR":"1438200","date":"18-Jul-2022","totalValueINR":"1438200","totalValueInUsd":"18086.8","indian_port":"MADRAS AIR","hs_no":"29349990","bill_no":"9599946","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"MSN HOUSE,PLOT NO.C-24,INDUSTRIAL E SANATH NAGAR,HYDERABAD"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1660933800,"product":"UBROGEPANT AMINE INTERMEDIATE","address":"MSN HOUSE,PLOT NO.C-24,INDUSTRIAL E SANATH NAGAR,HYDERABAD","city":"HYDERABAD TS","supplier":"ZHEJIANG SHINDAI CHEMICALS CO LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"MSN LIFE SCIENCES PRIVATE LTD","customerCountry":"INDIA","quantity":"1.90","actualQuantity":"1.9","unit":"KGS","unitRateFc":"68000","totalValueFC":"130714.7","currency":"USD","unitRateINR":"5474000","date":"20-Aug-2022","totalValueINR":"10400600","totalValueInUsd":"130714.7","indian_port":"MADRAS AIR","hs_no":"29349990","bill_no":"2081409","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"MSN HOUSE,PLOT NO.C-24,INDUSTRIAL E SANATH NAGAR,HYDERABAD"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1661711400,"product":"UBROGEPANT ACID INTERMEDIATE","address":"MSN HOUSE,PLOT NO.C-24,INDUSTRIAL E SANATH NAGAR,HYDERABAD","city":"HYDERABAD TS","supplier":"ZHEJIANG SHINDAI CHEMICALS CO LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"MSN LIFE SCIENCES PRIVATE LTD","customerCountry":"INDIA","quantity":"1.40","actualQuantity":"1.4","unit":"KGS","unitRateFc":"18000","totalValueFC":"25495.4","currency":"USD","unitRateINR":"1449000","date":"29-Aug-2022","totalValueINR":"2028600","totalValueInUsd":"25495.4","indian_port":"MADRAS AIR","hs_no":"29349990","bill_no":"2204122","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"MSN HOUSE,PLOT NO.C-24,INDUSTRIAL E SANATH NAGAR,HYDERABAD"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662748200,"product":"UBROGEPANT ACID INTERMEDIATE","address":"MSN HOUSE,PLOT NO.C-24,INDUSTRIAL E SANATH NAGAR,HYDERABAD","city":"HYDERABAD TS","supplier":"ZHEJIANG SHINDAI CHEMICALS CO LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"MSN LIFE SCIENCES PRIVATE LTD","customerCountry":"INDIA","quantity":"3.30","actualQuantity":"3.3","unit":"KGS","unitRateFc":"18000","totalValueFC":"59629","currency":"USD","unitRateINR":"1448100","date":"10-Sep-2022","totalValueINR":"4778730","totalValueInUsd":"59629","indian_port":"MADRAS AIR","hs_no":"29349990","bill_no":"2376972","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"MSN HOUSE,PLOT NO.C-24,INDUSTRIAL E SANATH NAGAR,HYDERABAD"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663957800,"product":"UBROGEPANT AMINE INTERMEDIATE","address":"MSN HOUSE,PLOT NO.C-24,INDUSTRIAL E SANATH NAGAR,HYDERABAD","city":"HYDERABAD TS","supplier":"ZHEJIANG SHINDAI CHEMICALS CO LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"MSN LIFE SCIENCES PRIVATE LTD","customerCountry":"INDIA","quantity":"2.10","actualQuantity":"2.1","unit":"KGS","unitRateFc":"68000","totalValueFC":"143261.4","currency":"USD","unitRateINR":"5467200","date":"24-Sep-2022","totalValueINR":"11481120","totalValueInUsd":"143261.4","indian_port":"MADRAS AIR","hs_no":"29349990","bill_no":"2588896","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"MSN HOUSE,PLOT NO.C-24,INDUSTRIAL E SANATH NAGAR,HYDERABAD"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734805800,"product":"UBROGEPANT IUPAC NAME:(3S)-N-[(3S,5S,6R)-6-METHYL-2-OXO-5-PHENYL-1-(2,2,2-TRIFLUOROETHYL)PIPERIDIN-3 -YL]-2-OXOSPIRO[1H-UBROGEPANT IUPAC NAME:(3S)-N-[(3S,5S,6R)-6-METHYL-2-OXO-5-PH","address":"NIKITA BAUNGLOW, NEAR PRAGATI","city":"GUJARAT","supplier":"NINGBO MINDO PHARMACEUTICAL COLTD","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"APOTHECON PHARMACEUTICALS PRIVATE LTD","customerCountry":"INDIA","quantity":"0.02","actualQuantity":"0.015","unit":"KGS","unitRateFc":"100666.7","totalValueFC":"1527.4","currency":"USD","unitRateINR":"8652300","date":"22-Dec-2024","totalValueINR":"129784.5","totalValueInUsd":"1527.4","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"7393618","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"ROOM 226,NO.43 XINGNING ROAD, YINZH OU DISTRICT,NINGBO ., ., CHINA SDNF CHINA","customerAddress":"NIKITA BAUNGLOW, NEAR PRAGATI"}]
17-May-2022
21-Apr-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

read-more
read-more

01

Brand Name : Ubrelvy

U.S.A

Ubrogepant

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 125

2019 Revenue in Millions : 0

Growth (%) : New Launch

Abbvie Company Banner

02

05

Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

ABBVIE

U.S.A

UBROGEPANT

US Patent Number : 9499545

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 211765

Patent Use Code : U-2718

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-11-10

Abbvie Company Banner

02

ABBVIE

U.S.A

UBROGEPANT

US Patent Number : 12310953

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 211765

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-01-30

Abbvie Company Banner

03

ABBVIE

U.S.A

UBROGEPANT

US Patent Number : 12220408

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 211765

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-01-30

Abbvie Company Banner

04

ABBVIE

U.S.A

UBROGEPANT

US Patent Number : 8754096

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 211765

Patent Use Code : U-2717

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-07-19

Abbvie Company Banner

05

ABBVIE

U.S.A

UBROGEPANT

US Patent Number : 9833448

Drug Substance Claim :

Drug Product Claim :

Application Number : 211765

Patent Use Code : U-2718

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-11-10

Abbvie Company Banner

06

ABBVIE

U.S.A

UBROGEPANT

US Patent Number : 8912210

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 211765

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-12-23

Abbvie Company Banner

07

ABBVIE

U.S.A

UBROGEPANT

US Patent Number : 8912210

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 211765

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-12-23

Abbvie Company Banner

08

ABBVIE

U.S.A

UBROGEPANT

US Patent Number : 11857542

Drug Substance Claim :

Drug Product Claim :

Application Number : 211765

Patent Use Code : U-3786

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2041-12-22

Abbvie Company Banner

09

ABBVIE

U.S.A

UBROGEPANT

US Patent Number : 9833448

Drug Substance Claim :

Drug Product Claim :

Application Number : 211765

Patent Use Code : U-2718

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-11-10

Abbvie Company Banner

10

ABBVIE

U.S.A

UBROGEPANT

US Patent Number : 8754096

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 211765

Patent Use Code : U-2717

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-07-19

Abbvie Company Banner
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 1374248-77-7 / Ubrogepant API manufacturers, exporters & distributors?

Ubrogepant manufacturers, exporters & distributors 1

63

PharmaCompass offers a list of Ubrogepant API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ubrogepant manufacturer or Ubrogepant supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ubrogepant manufacturer or Ubrogepant supplier.

PharmaCompass also assists you with knowing the Ubrogepant API Price utilized in the formulation of products. Ubrogepant API Price is not always fixed or binding as the Ubrogepant Price is obtained through a variety of data sources. The Ubrogepant Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Ubrogepant

Synonyms

1374248-77-7, Ubrelvy, Mk-1602, Ubrogepant anhydrous, Ad0o8x2qjr, (3's)-n-((3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro(cyclopenta(b)pyridine-6,3'-pyrrolo(2,3-b)pyridine)-3-carboxamide

Cas Number

1374248-77-7

Unique Ingredient Identifier (UNII)

AD0O8X2QJR

About Ubrogepant

Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant] remain in clinical development. Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative to its predecessors. Several parenteral monoclonal antibodies acting against the CGRP pathway (e.g. [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years. Compared to the current standard of therapy for migraine treatment, namely triptans such as [sumatriptan] and [almotriptan], CGRP antagonists present several advantages. They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular disease. The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment of this debilitating condition.

Ubrogepant Manufacturers

A Ubrogepant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ubrogepant, including repackagers and relabelers. The FDA regulates Ubrogepant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ubrogepant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Ubrogepant manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Ubrogepant Suppliers

A Ubrogepant supplier is an individual or a company that provides Ubrogepant active pharmaceutical ingredient (API) or Ubrogepant finished formulations upon request. The Ubrogepant suppliers may include Ubrogepant API manufacturers, exporters, distributors and traders.

click here to find a list of Ubrogepant suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Ubrogepant USDMF

A Ubrogepant DMF (Drug Master File) is a document detailing the whole manufacturing process of Ubrogepant active pharmaceutical ingredient (API) in detail. Different forms of Ubrogepant DMFs exist exist since differing nations have different regulations, such as Ubrogepant USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Ubrogepant DMF submitted to regulatory agencies in the US is known as a USDMF. Ubrogepant USDMF includes data on Ubrogepant's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ubrogepant USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Ubrogepant suppliers with USDMF on PharmaCompass.

Ubrogepant NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ubrogepant as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Ubrogepant API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Ubrogepant as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Ubrogepant and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ubrogepant NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Ubrogepant suppliers with NDC on PharmaCompass.

Ubrogepant GMP

Ubrogepant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Ubrogepant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ubrogepant GMP manufacturer or Ubrogepant GMP API supplier for your needs.

Ubrogepant CoA

A Ubrogepant CoA (Certificate of Analysis) is a formal document that attests to Ubrogepant's compliance with Ubrogepant specifications and serves as a tool for batch-level quality control.

Ubrogepant CoA mostly includes findings from lab analyses of a specific batch. For each Ubrogepant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Ubrogepant may be tested according to a variety of international standards, such as European Pharmacopoeia (Ubrogepant EP), Ubrogepant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ubrogepant USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty